Vallerie V. Mclaughlin

Vallerie V. Mclaughlin's AcademicInfluence.com Rankings

Philosophy

#9397

World Rank

#12951

Historical Rank

Logic

#6378

World Rank

#7890

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Vallerie V. Mclaughlin's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Vallerie V. Mclaughlin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Vallerie V. Mclaughlin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy (2002) (1225)
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease (2000) (1084)
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 (2008) (915)
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015) (819)
Sitaxsentan therapy for pulmonary arterial hypertension. (2004) (739)
Selexipag for the Treatment of Pulmonary Arterial Hypertension. (2014) (641)
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. (2006) (613)
Beraprost therapy for pulmonary arterial hypertension. (2003) (608)
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study (2013) (604)
Survival with first-line bosentan in patients with primary pulmonary hypertension (2005) (600)
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines (2004) (558)
Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. (2004) (530)
ACCF/AHA Expert Conseusus Document (2009) (530)
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. (2006) (518)
Updated evidence-based treatment algorithm in pulmonary arterial hypertension. (2009) (512)
Risk stratification and medical therapy of pulmonary arterial hypertension (2019) (507)
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. (2010) (488)
[Updated treatment algorithm of pulmonary arterial hypertension]. (2014) (421)
Modern age pathology of pulmonary arterial hypertension. (2012) (417)
Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. (2007) (378)
The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. (1998) (363)
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. (2004) (303)
Management of pulmonary arterial hypertension. (2015) (295)
Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. (2006) (287)
Updated treatment algorithm of pulmonary arterial hypertension. (2013) (272)
An overview of the 6th World Symposium on Pulmonary Hypertension (2019) (268)
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. (2002) (251)
End points and clinical trial design in pulmonary arterial hypertension. (2004) (246)
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. (2009) (236)
Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension (2003) (229)
Prostanoid therapy for pulmonary arterial hypertension. (2004) (229)
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. (2011) (223)
Endothelin Receptor Blockers in Cardiovascular Disease (2003) (213)
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol (2005) (210)
Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. (2005) (205)
Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series (1999) (205)
[Treatment goals of pulmonary hypertension]. (2014) (195)
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension (2015) (192)
Pulmonary Diseases and the Heart (2007) (190)
Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. (2013) (185)
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. (2006) (175)
Acute Right Ventricular Failure in the Setting of Acute Pulmonary Embolism or Chronic Pulmonary Hypertension: A Detailed Review of the Pathophysiology, Diagnosis, and Management (2008) (169)
Pulmonary arterial hypertension. (2011) (158)
Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. (2002) (158)
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. (2005) (157)
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial (2015) (140)
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey (2012) (126)
Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. (2013) (124)
Evidence-Based Clinical Practice Guidelines (2004) (117)
Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. (2013) (117)
Sotatercept for the Treatment of Pulmonary Arterial Hypertension. (2021) (105)
Treatment of pulmonary hypertension. (2016) (103)
Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. (2005) (99)
Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. (2007) (98)
Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. (2011) (96)
Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006. (2007) (95)
Treatment goals of pulmonary hypertension. (2013) (92)
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension (2017) (92)
Evidence-Based Clinical Practice Guidelines Hypertension: Updated ACCP Medical Therapy for Pulmonary Arterial (2007) (90)
Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease (2007) (89)
Temporal trends and drug exposures in pulmonary hypertension: an American experience. (2006) (89)
Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry (2012) (87)
Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. (2004) (86)
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. (2009) (83)
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. (2018) (77)
ACCP Evidence-Based Clinical Practice Guidelines (2004) (74)
Modern age pathology of pulmonary arterial hypertension (2012) (73)
Erratum: "Survival with first-line bosentan in patients with primary pulmonary hypertension" (European Respiratory Journal (2005) vol. 25 (244-249)) (2005) (65)
The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH (2011) (65)
Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. (2013) (65)
The 4th World Symposium on Pulmonary Hypertension. Introduction. (2009) (65)
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study (2018) (63)
Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. (2010) (62)
Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. (2017) (60)
Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusion (2008) (59)
Looking to the future: a new decade of pulmonary arterial hypertension therapy (2011) (58)
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. (2007) (56)
Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study (2015) (53)
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. (2016) (52)
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. (2021) (49)
Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management. (2018) (47)
Successful management of pregnancy in a patient with eisenmenger syndrome with epoprostenol. (2003) (46)
Depressive Symptoms in Pulmonary Arterial Hypertension: Prevalence and Association With Functional Status (2010) (46)
Pulmonary Arterial Hypertension (2006) (45)
Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study (2014) (45)
Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. (2007) (45)
Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. (2010) (44)
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. (2019) (44)
Increased CD39 Nucleotidase Activity on Microparticles from Patients with Idiopathic Pulmonary Arterial Hypertension (2012) (43)
Detection of subclinical cardiovascular disease: the emerging role of electron beam computed tomography. (2002) (42)
Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis (2019) (42)
Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. (2013) (42)
Long-term treatment with sildenafil citrate in pulmonary arterial hypertension (2008) (41)
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. (2021) (38)
ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (2006) (36)
Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study (2014) (35)
Pulmonary Hypertension: Types and Treatments (2014) (33)
Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis (2019) (33)
Psychometric Validation of the Pulmonary Arterial Hypertension‐Symptoms and Impact (PAH‐SYMPACT) Questionnaire: Results of the SYMPHONY Trial (2018) (32)
Pulmonary arterial hypertension: tailoring treatment to risk in the current era (2017) (32)
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study (2019) (31)
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension (2019) (31)
Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. (2019) (28)
Pulmonary hypertension--advances in medical and surgical interventions. (1998) (26)
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. (2014) (26)
Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. (2016) (26)
One-year experience with intravenous treprostinil for pulmonary arterial hypertension. (2013) (25)
Classification and epidemiology of pulmonary hypertension. (2004) (25)
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial (2019) (24)
Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study (2020) (23)
Right atrial strain is predictive of clinical outcomes and invasive hemodynamic data in group 1 pulmonary arterial hypertension (2016) (23)
Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. (2014) (22)
Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis (2020) (22)
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. (2019) (21)
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study (2017) (20)
Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. (2003) (20)
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents. (2019) (19)
Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report (2018) (19)
Managing pulmonary arterial hypertension and optimizing treatment options: prognosis of pulmonary artery hypertension. (2013) (19)
Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort (2017) (18)
Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin. (1999) (18)
Future perspectives in pulmonary arterial hypertension (2016) (18)
Safety and Efficacy of IV Treprostinil for Pulmonary Arterial Hypertension * (2006) (17)
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial. (2019) (16)
Effect of Bosentan and Sildenafil Combination Therapy on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the COMPASS-2 Study (2014) (16)
Association of NT-proBNP and Long-Term Outcome in Patients with Pulmonary Arterial Hypertension: Insights from the Phase III GRIPHON Study (2019) (16)
Erratum: Beraprost therapy for pulmonary arterial hypertension (Journal of the American College of Cardiology (2003) 41 (2119-2125)) (2003) (16)
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension (2022) (15)
Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries (2021) (15)
Barriers to physical activity in patients with pulmonary hypertension (2019) (15)
Results from the United States CTEPH Registry (US-CTEPH-R): Enrollment Characteristics and 1-Year Follow-up. (2021) (14)
Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. (2021) (14)
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. (2017) (13)
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study (2021) (13)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ILOPROST INHALATION AS ADD-ON THERAPY TO BOSENTAN IN PULMONARY ARTERIAL HYPERTENSION (PAH) (2005) (13)
Pulmonary arterial hypertension: bridging the present to the future (2012) (13)
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension (2021) (13)
Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension (2019) (12)
TRIUMPH 1: Long-Term Safety and Efficacy of Inhaled Treprostinil Sodium in Patients with Pulmonary Arterial Hypertension (PAH) – Two Year Follow-Up. (2009) (12)
Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort (2021) (10)
Sitaxsentan Improves 6MW in Patients with Pulmonary Arterial Hypertension (PAH) Related to Connective-Tissue Diseases (CTD) (2004) (10)
Has the 6-min walk distance run its course? (2012) (9)
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. (2021) (9)
Clinical and angiographic profile of patients with markedly elevated coronary calcium scores (>or=1000) detected by electron beam computed tomography. (2004) (8)
Safety of regadenoson stress testing in patients with pulmonary hypertension (2018) (8)
Pulmonary Hypertension in Women. (2019) (8)
The ARROW Study: A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study of Selonsertib in Subjects with Pulmonary Arterial Hypertension (2017) (8)
Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It! (2015) (7)
Sickle cell disease-associated pulmonary hypertension: a coat of many colors. (2007) (7)
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension (2021) (7)
Usefulness of Echocardiography/Doppler to Reliably Predict Elevated Left Ventricular End-Diastolic Pressure in Patients With Pulmonary Hypertension. (2017) (7)
Pulmonary Hypertension The Effects of Chronic Prostacyclin Therapy on Cardiac Output and Symptoms in Primary Pulmonary Hypertension (2016) (7)
Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH (2020) (6)
PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH) (2019) (6)
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. (2021) (6)
Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps (2021) (6)
Pulmonary hypertension. (2004) (6)
An insider view on the World Symposium on Pulmonary Hypertension. (2019) (6)
Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative. (2014) (6)
Physical activity and quality of life in patients with pulmonary hypertension (2019) (6)
Improving patient outcomes in pulmonary hypertension (2015) (6)
Pulmonary hypertension: Preface (2001) (6)
OPUS Registry: Treatment Patterns and Safety of Macitentan in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (PAH-SSc) (2017) (5)
The metabolic syndrome and pulmonary vascular disease. (2009) (5)
Pulmonary arterial hypertension: Current diagnosis and management (2002) (5)
Beast of Pulmonary Arterial Hypertension Burden. (2016) (5)
Update on pulmonary arterial hypertension research: proceedings from a meeting of experts (2018) (5)
Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study (2020) (5)
TRANSITION FROM EPOPROSTENOL TO TREPROSTINIL IN PULMONARY ARTERIAL HYPERTENSION: A CONTROLLED TRIAL (2006) (4)
REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal (2017) (4)
An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis: The DETECT Study (2012) (4)
Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities (2019) (4)
Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry (2021) (4)
Macitentan in pulmonary hypertension (PH): Data from OPUS and OrPHeUS real-world data sets (2019) (4)
Medical management of primary pulmonary hypertension (2002) (4)
A paradigm shift in pulmonary arterial hypertension management (2013) (4)
Upfront Combination Therapy With Ambrisentan and TadalafilIin Treatment Naive Patients With Pulmonary Arterial Hypertension (PAH): Subgroup Analyses by Functional Class (FC), Etiology, and Region From the AMBITION Study (2014) (3)
OPUS Registry: Safety and Tolerability of Macitentan in a Real-World Setting (2017) (3)
TRIUMPH: LONG-TERM EFFICACY AND SAFETY OF INHALED TREPROSTINIL SODIUM IN PULMONARY ARTERIAL HYPERTENSION (PAH) (2008) (3)
New horizons in pulmonary arterial hypertension management (2014) (3)
PCV3 Hospitalization Rates and Association with Survival Risk at Baseline in Patients with Pulmonary Artery Hypertension (PAH) Receiving Selexipag in Real-World (RW) Clinical Practice (2020) (3)
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. (2023) (3)
Opportunities and challenges in the study of pulmonary arterial hypertension. (2009) (3)
Does the outcome justify an oral-first treatment strategy for management of pulmonary arterial hypertension? (2011) (3)
The evolving landscape of pulmonary arterial hypertension clinical trials (2022) (3)
Treatment of Pulmonary Arterial Hypertension (PAH): Data from the Quality Enhancement Research Initiative. (2009) (3)
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study (2020) (3)
Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION (2021) (3)
Contemporary Trends in the Diagnosis and Management of PAH: An Initiative To Close the Care Gap (2010) (3)
Reponse to Inhaled Nitric Oxide (iNO) Does Not Predict Long Term Mortality in Pulmonary Arterial Hypertension (PAH). (2009) (3)
Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH) (2015) (3)
THE OPSUMIT® USERS REGISTRY: A GENDER SUBGROUP ANALYSIS OF PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND SURVIVAL IN PULMONARY ARTERIAL HYPERTENSION (2018) (2)
DIAGNOSTIC WORK UP OF PAH: DATA FROM THE QUALITY ENHANCEMENT RESEARCH INITIATIVE (2007) (2)
'Raising the bar' for the treatment of pulmonary arterial hypertension. (2006) (2)
United States CTEPH Registry: Differences Between Operated and Non-Operated Subjects in Baseline Data and 1-Year Outcomes (2020) (2)
McLaughlin and McGoon Pulmonary Arterial Hypertension (2006) (2)
Depressive Symptoms in Pulmonary Arterial Hypertension: Prevalence and Impact on Functional Status. (2009) (2)
Periprocedural Complications With Balloon Pulmonary Angioplasty: Analysis of Global Studies. (2023) (2)
Vasodilator response in scleroderma-related pulmonary arterial hypertension (2006) (2)
ONE YEAR EXPERIENCE WITH INTRAVENOUS TREPROSTINIL IN PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENTS (2005) (2)
Study Design of the Phase 3 ADVANCE Program Evaluating Time-to-Clinical Events and Exercise Capacity in Patients with Pulmonary Arterial Hypertension Treated with Ralinepag (2019) (2)
Early selexipag initiation and long-term outcomes: Insights from RCTs in PAH (2022) (2)
Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States (2020) (2)
Preliminary Data from the United States CTEPH Registry (2017) (2)
Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis (2021) (2)
Management of selexipag interruptions in the GRIPHON study (2016) (2)
Prostacyclin Therapy for Pulmonary Arterial Hypertension (2008) (2)
REAL-WORLD DATA FOR SELEXIPAG IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: A SPHERE (SELEXIPAG: THE USERS DRUG REGISTRY) ANALYSIS (2020) (2)
The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study (2021) (2)
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results (2015) (2)
CONTINUOUS SUBCUTANEOUS INFUSION OF REMODULIN, A PROSTACYCLIN ANALOGUE, IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: LONG-TERM OUTCOME (ABSTRACT 1203) (2001) (2)
OP0267 Initial Combination Therapy of Ambrisentan and Tadalafil in Connective Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH): Subgroup Analysis from the Ambition Trial (2015) (2)
Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study (2020) (2)
Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study (2016) (2)
Introduction: devising a prognostic score for pulmonary arterial hypertension. (2012) (2)
Combination therapy with macitentan and phosphodiesterase type-5 inhibitor (PDE5i) in pulmonary arterial hypertension (PAH): real-world data from OPUS and OrPHeUS (2020) (1)
3016Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension (2018) (1)
Real-World Upfront Combination Therapy with Macitentan and Tadalafil in Pulmonary Arterial Hypertension (PAH): Data from the Combined OPUS and OrPHeUS Datasets (2020) (1)
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension (2021) (1)
Mortality in Patients with PAH in the Modern Era: Data from the Quality Enhancement Research Initiative. (2009) (1)
Treatment with macitentan for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): real-world experience from the combined OPUS and OrPHeUS data sets (2020) (1)
Systematic Collection of Human Pulmonary Arterial Hypertension Lung Tissue: Methods of the Pulmonary Hypertension Breakthrough Initiative (PHBI). (2009) (1)
MACITENTAN IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE: REAL-WORLD EVIDENCE FROM THE COMBINED OPUS/ORPHEUS DATA SETS (2019) (1)
SAFETY OF MACITENTAN IN PULMONARY HYPERTENSION PATIENTS WITH ELEVATED PULMONARY CAPILLARY WEDGE PRESSURE: REAL-WORLD EVIDENCE FROM OPUS/ORPHEUS (2021) (1)
Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension: A STS Database Analysis (2021) (1)
Lower Socioeconomic Status Associated with Decreased Completion of Exercise Rehabilitation in Patients with Pulmonary Hypertension (2019) (1)
SELEXIPAG FOR PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE (PAH-CHD) AFTER DEFECT CORRECTION: INSIGHTS FROM THE RANDOMISED CONTROLLED GRIPHON STUDY (2016) (1)
US CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) REGISTRY: SURVIVAL AND HOSPITALIZATION OUTCOMES (2022) (1)
Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Real-World Experience with Macitentan (2019) (1)
Macitentan in Pulmonary Hypertension (PH) Due to Chronic Lung Disease: Real-World Evidence from OPUS/OrPHeUS (2021) (1)
Pulmonary Hypertension Roundtable: Recapping 5 Years, Exploring Emerging Approaches (2006) (1)
Pulmonary Hypertension in Women: What Does the Cardiologist Need to Know? (2017) (1)
Ralinepag Plasma Levels Correlate with Improvements in Functional and Hemodynamic Parameters in Patients with Pulmonary Arterial Hypertension (2019) (1)
Clinical Course of Patients Transitioned from Another Prostacyclin Pathway Agent (PPA) to Selexipag in SPHERE (2019) (1)
Assessment of the REPLACE Study Composite Endpoint in the PATENT Study and Association with Long-Term Outcomes in Riociguat-Treated Patients (2019) (1)
INHALED IMATINIB FOR PULMONARY ARTERIAL HYPERTENSION CLINICAL TRIAL: DESIGN OF THE IMPACT PHASE 2B/3 STUDY DESIGN (2022) (1)
PHYSICAL ACTIVITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY HYPERTENSION (2019) (1)
Real-World Evidence from the OPUS Registry: An Insight into Pulmonary Arterial Hypertension Risk Assessment Parameters in Clinical Practice (2019) (1)
MACITENTAN IN THE ELDERLY POPULATION WITH PULMONARY ARTERIAL HYPERTENSION: REAL-WORLD EVIDENCE FROM THE COMBINED OPUS REGISTRY AND ORPHEUS COHORT (2019) (1)
United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol Design. (2021) (1)
Abstract 10188: Sotatercept Phase 3 Program Design and Rationale: A Novel Treatment for Pulmonary Arterial Hypertension (2021) (1)
Interventional Imaging Roadmap to Successful Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension (2022) (1)
SWITCHING TO RIOCIGUAT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION NOT AT TREATMENT GOAL WITH PHOSPHODIESTERASE TYPE-5 INHIBITORS: SUBGROUP ANALYSIS RESULTS OF THE REPLACE STUDY (2020) (1)
TREATMENT PATTERNS IN PULMONARY ARTERIAL HYPERTENSION: CHANGES IN CLINICAL PRACTICE OVER TIME USING REAL-WORLD EVIDENCE FROM THE COMBINED OPUS/ORPHEUS DATA SETS (2020) (1)
Prostacyclin for Secondary Pulmonary Hypertension (2000) (0)
CLINICAL CHARACTERISTICS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND TREATMENT PATTERNS: A REAL-WORLD ANALYSIS FROM SPHERE (SELEXIPAG: THE USERS DRUG REGISTRY) (2021) (0)
Macitentan in portopulmonary hypertension (PoPH): Real-world data from OPUS and OrPHeUS (2019) (0)
Advance Outcomes - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in Subjects with Pulmonary Arterial Hypertension (2020) (0)
Abstract 56: Differences Between Chronic Thromboembolic Disease And Chronic Thromboembolic Pulmonary Hypertension Patients At Time Of Presentation (2022) (0)
PROSTACYCLIN INTERNATIONAL EXPERT PANEL CONSENSUS-BASED RECOMMENDATIONS FOR THE USE OF SELEXIPAG IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (2019) (0)
Interim analysis of pulmonary arterial hypertension (PAH)-targeted background therapy in SPHERE (SelexiPag: tHe usErs dRug rEgistry) (2018) (0)
FRI0539 SURVIVAL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (CTD-PAH): A META-ANALYSIS OF OBSERVATIONAL REGISTRIES (2020) (0)
Correlations between basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and clinical features of pulmonary arterial hypertension (PAH) (2002) (0)
Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry (2018) (0)
Contributors (2012) (0)
56 Veletri® and Flolan® (Epoprostenol Sodium) in the Treatment of Pulmonary Arterial Hypertension (2012) (0)
TheShort-term Effects ofDigoxin in Patients WithRight Ventricular Dysfunction FromPulmonary Hypertension* (2015) (0)
Patient Characteristics and Treatment Patterns with Macitentan in Pulmonary Arterial Hypertension: Insights from the OPUS Registry (2019) (0)
Decision Making in Advanced PAH: Palliative Care and Hospice or Parenteral Prostacyclin? (2016) (0)
Evidence-Based Clinical Practice Guidelines Medical Therapy For Pulmonary Arterial Hypertension : ACCP (2004) (0)
The Safety And Therapeutic Efficiency Of Warfarin In Pulmonary Arterial Hypertension (2012) (0)
Oral and Subcutaneous Prostacyclin Analogs: Analyzing the Latest Evidence on Efficacy and Safety (2002) (0)
S94 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON (2021) (0)
27. Pulmonary Hypertension (2013) (0)
Abstract 11997: Impact of Barriers to Physical Activity on Daily Step Counts in Pulmonary Hypertension Patients (2018) (0)
Exercise Parameters Predict the Development of Scleroderma-Associated Pulmonary Arterial Hypertension (2019) (0)
U-M Physicians Listed Among the Best Doctors in America 2007 Listed by primary specialty; additional specialty listings are given in parentheses. A * indicates a physician with an adjunct faculty appointment and a primary practice in the community. (2007) (0)
Increased CD39 Expression on Circulating Platelet Microparticles in Patients with Primary Pulmonary Hypertension. (2009) (0)
Predictors for survival in scleroderma-related pulmonary arterial hypertension (2006) (0)
Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS) (2022) (0)
NYHA Functional Class II: An Achievable Goal for All Patients with Pulmonary Arterial Hypertension Receiving Treatment (2009) (0)
PCV2 Characterizing Patients Treated with Macitentan: Real-World Evidence and a Randomized Controlled Trial Cohort (2020) (0)
Pulmonary Hypertension 12 . 1 : Pulmonary Hypertension (0)
RACIAL DISPARITIES IN PULMONARY EMBOLISM MORTALITY AMONGST US ADULTS BEFORE AND DURING COVID-19 PANDEMIC. (2023) (0)
Pulmonary hypertension: Hemodynamic assessment and response to vasodilators (2010) (0)
Pulmoner hipertansiyonda tedavi hedefleri Treatment goals of pulmonary hypertension (2014) (0)
Pulmonary Hypertension Roundtable: Integrating Current Strategies for Continuing Assessment of Pulmonary Arterial Hypertension (2005) (0)
P3674Patient characteristics and treatment patterns in the multicentre, retrospective chart review of first-time Opsumit (macitentan) users in the United States (OrPHeUS) (2019) (0)
DOSE PROPORTIONALITY OF TREPROSTINIL SODIUM (REMODULIN) ADMINISTERED BY CONTINUOUS SUBCUTANEOUS AND INTRAVENOUS INFUSION (2007) (0)
Erratum: (Journal of Medical Genetics (2003) 40 (865-871)) (2004) (0)
PHA Achieves Educational Breakthrough With New Interactive CD-ROM (2005) (0)
Selexipag Use: Characterization of the First 500 Patients (pts) in SPHERE (SelexiPag: tHe usErs dRug rEgistry) by World Health Organization (WHO) Functional Class (FC) (2020) (0)
S122 Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension (2018) (0)
Passing the Torch: New Editorial Team Offers Broadest Spectrum of Expert Medical Opinion in Pulmonary Hypertension (2005) (0)
SAFETY OF BALLOON PULMONARY ANGIOPLASTY IN THE OUTPATIENT SETTING: THE MICHIGAN MEDICINE EXPERIENCE (2023) (0)
Abstract 57: Impact Of Body Mass Index In Functional Capacity And Hemodynamics In Patients With Pulmonary Arterial Hypertension (2022) (0)
Risk Assessment at Baseline and One Year in Patients with Pulmonary Arterial Hypertension (PAH): Data from the First 250 Patients Enrolled in SPHERE (Uptravi® [SelexiPag]: tHe UsErs dRug registry) (2019) (0)
LONG-TERM CLINICAL COURSE OF THE FIRST 250 PATIENTS TREATED WITH SELEXIPAG IN REAL-WORLD SETTINGS FROM THE SPHERE REGISTRY (SELEXIPAG:THE USERS DRUG REGISTRY) (2019) (0)
PHA Web Site—www.phassociation.org—Best Kept Secret on the Internet (2005) (0)
Using a knowledge translation program to facilitate guideline‐ and evidence‐based patient management: the PAH‐QuERI Extension Program (2022) (0)
Prostacyclins: Intravenous, subcutaneous, inhaled and oral (2011) (0)
TEMPORAL MORTALITY TRENDS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, STROKE, AND PULMONARY EMBOLISM IN THE UNITED STATES (2023) (0)
Pulmonary Diseases and the Heart Cardiovascular Involvement in General Medical Conditions (2007) (0)
Abstract 160: Comparison of Baseline Characteristics Among World Health Organization Groups in Pulmonary Hypertension (2019) (0)
TIMELY DETECTION OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH REPAIRED CONGENITAL HEART DISEASE: INTERIM RESULTS FROM THE ACHD-QUERI REGISTRY (2017) (0)
826 RePHerral Study: A Multi-Center Study on the Referrals for Pulmonary Hypertension (PH); Left Heart Disease and PH (2012) (0)
Differences in Lymphocyte Surface Nucleotidases in Patients with Pulmonary Hypertension. (2009) (0)
Assessment of the REPLACE study composite endpoint in the PATENT study and association with long-term outcomes in riociguat-treated patients. (2020) (0)
TAKE MY BREATH AWAY: RARE MIMIC IN THE DIAGNOSIS OF PULMONARY HYPERTENSION (2023) (0)
Treatment of pulmonary arterial hypertension associated with congenital heart disease with intravenous epoprostenol: impact of therapy on timing of transplantation (2002) (0)
Is The Clinical Decision To Begin Oral Therapy Rather Than Prostacyclins In Pulmonary Arterial Hypertension Justified By The Outcome (2010) (0)
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH MILDLY-ELEVATED PRESSURES (MEP) AND PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM OPUS/ORPHEUS (2021) (0)
Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry (2020) (0)
P3671Selexipag dosing and titration in the first 500 patients enrolled in SPHERE (SelexiPag: tHe UsErs dRug rEgistry) (2019) (0)
Assessment Of The French Formula For Mortality Prediction In PAH (2012) (0)
EXPLORING BARRIERS AND FACILITATORS TO ADVANCEMENT AMONG WOMEN FACULTY IN CARDIOVASCULAR MEDICINE (2022) (0)
Lung transplantation for pulmonary hypertension: patient selection and maintenance therapy while awaiting transplantation (1998) (0)
Mortality of idiopathic / hereditary and connective tissue disease-associated pulmonary arterial hypertension : the data from first single-center prospective registry in Indonesia (2021) (0)
Optimizing the Care of Pulmonary Arterial Hypertension: The Importance of Functional Class and the Specific Challenges of Eisenmenger Syndrome (2011) (0)
Safe and Effective Balloon Pulmonary Angioplasty in the Outpatient Setting: The Michigan Medicine Experience (2023) (0)
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension (2023) (0)
Abstract 193: Who Group III Pulmonary Hypertension Patients With Lower Socioeconomic Status Are Diagnosed at a Younger Age (2019) (0)
Screening for PAH in Scleroderma: Identifying Hallmarks of the Disease and Optimal Treatment Strategies (2002) (0)
In Search of Elusive “Roadmap to a Cure,’ PH Community Finds Another Touchstone at Scientific Sessions (2006) (0)
Real-World Mono-, Double and Triple Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Evidence from the Combined OPUS/OrPHeUS Dataset (2020) (0)
AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study (2022) (0)
Percutaneous Endovascular Ultrasound Pulmonary Artery Denervation for the Treatment of Pulmonary Arterial Hypertension: 12-Month Results of the Trophy 1 Study (2020) (0)
Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled GB002 for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension (2021) (0)
P4673Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): combined data from OPUS and OrPHeUS real-world data sets (2019) (0)
PROSPECT Patient Subgroups and Etiologies: Predictors of Outcomes (2013) (0)
Abstract 14896: Does Echocardiography/Doppler Reliably Predict Elevated LVEDP? (2015) (0)
Communications to the EditorSitaxsentan in Pulmonary Arterial Hypertension (2003) (0)
COMORBIDITIES IN PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM THE REAL-WORLD OPSUMIT® USERS (OPUS) REGISTRY (2020) (0)
Chronicling the Evolution of a Journal: We Welcome New Support to Meet Growing Educational Needs of Physicians (2006) (0)
IMPACT OF ROUTINE USAGE OF THE DETECT SCORE ON DISEASE SEVERITY AT DIAGNOSIS OF SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: A SINGLE TERTIARY REFERRAL CENTER EXPERIENCE (2020) (0)
Reflecting on Progress in PH and Appreciating the Contributions of Our Physicians (2006) (0)
Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) (2016) (0)
PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH) (2021) (0)
Switching from PDE5i to riociguat in patients with PAH: A responder analysis from REPLACE (2021) (0)
Pulmonary arterial hypertension: New management options (2004) (0)
FUNCTIONAL CLASS AND PHYSICIAN-PERCEIVED SEVERITY ARE SIMILAR IN TREATED AND UNTREATED PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: A REAL-WORLD SURVEY (2021) (0)
Abstract 11192: Diagnosis and Management of PAH: An Initiative to Close the Care Gap (2010) (0)
US CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) REGISTRY: LONGITUDINAL QUALITY-OF-LIFE RESULTS (2022) (0)
Hands Across the Ocean: Building a Bridge to an International Pulmonary Hypertension Community (2006) (0)
Value Of Hemodynamic Parameters And Calculated Indices Of Right Ventricular Function In Predicting Mortality In Pulmonary Arterial Hypertension (2010) (0)
Impact of Patient-Perceived Barriers to Exercise Therapy on Referral to Exercise Rehabilitation in Pulmonary Hypertension Patients (2019) (0)
Initial Triple Oral Therapy in Pulmonary Arterial Hypertension (PAH): Extended Long-Term Outcome Data from TRITON (2021) (0)
The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study (Preprint) (2020) (0)
MACITENTAN IN PORTOPULMONARY HYPERTENSION: REAL-WORLD EVIDENCE FROM THE OPSUMIT USERS REGISTRY (2018) (0)
OPUS Registry: Switching to Macitentan From Other Endothelin Receptor Antagonists (ERAs) (2018) (0)
Hemodynamic Effects of the Oral Prostacyclin (IP) Receptor Agonist Ralinepag in Pulmonary Arterial Hypertension (2017) (0)
Interim Results from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension (2019) (0)
DIFFERENCES BETWEEN PULMONARY ARTERIAL HYPERTENSION PATIENTS AND PULMONARY VENO-OCCLUSIVE DISEASE/PULMONARY CAPILLARY HEMANGIOMATOSIS PATIENTS AT TIME OF PRESENTATION (2020) (0)
P3560Real-world experience with concomitant macitentan and riociguat treatment in patients with pulmonary hypertension (PH) in the OPsumit USers (OPUS) registry (2018) (0)
SAFE AND EFFECTIVE LESION CROSSING IN BALLOON PULMONARY ANGIOPLASTY: THERAPEUTIC WINDOW FOR A NOVEL DEVICE (2022) (0)
ATS Meeting Serves as Useful Measure Of Rising Interest in Pulmonary Hypertension (2005) (0)
Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON (2020) (0)
LONG-TERM TREATMENT WITH SITAXSENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE (PAH-CTD) (2005) (0)
TREATMENT OF PAH: DATA FROM THE QUALITY ENHANCEMENT RESEARCH INITIATIVE (2007) (0)
55 RePHerral Study: A Multi-Center Study on the Referral of Pulmonary Hypertension Patients (2012) (0)
Macitentan in incident and prevalent pulmonary arterial hypertension (PAH): OPUS/OrPHeUS real-world data (2020) (0)
Reassessing Patients Over Time : How To Follow Patients on Treatment (2009) (0)
Current status and barriers in pulmonary hypertension care delivery in India: A qualitative analysis (2022) (0)
Evidence-Based Clinical Practice Guidelines : Updated ACCP * Hypertension Medical Therapy for Pulmonary Arterial (2007) (0)
EXPERIENCE WITH MACITENTAN TRIPLE COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION: REAL-WORLD EVIDENCE FROM THE OPUS REGISTRY (2020) (0)
REVEAL LITE 2 RISK ASSESSMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION FROM THE GRIPHON STUDY: A POST-HOC ANALYSIS DEMONSTRATES ASSOCIATION OF RISK STATUS WITH LONG-TERM OUTCOMES (2021) (0)
68 – Pulmonary Hypertension (2012) (0)
Characteristics and clinical course of the first 500 patients (pts) from SPHERE (SelexiPag: tHe usErs dRug rEgistry) receiving selexipag in real-world clinical practice (2020) (0)
LEFT ATRIAL AND LEFT VENTRICULAR STRAIN DURING EXERCISE UNMASK DIASTOLIC DYSFUNCTION IN SCLERODERMA (2020) (0)
Clinical Perspectives in Pulmonary Arterial Hypertension INTRODUCTIONS (2010) (0)
Characteristics of Patients With CTD-associated PAH Treated With Selexipag in the Real-world Setting: Interim Data From the SPHERE Registry (2018) (0)
Profiles in pulmonary hypertension and pulmonary embolism (2013) (0)

This paper list is powered by the following services:

Vallerie V. Mclaughlin's Academic­Influence.com Rankings

Vallerie V. Mclaughlin's Degrees

Why Is Vallerie V. Mclaughlin Influential?

Vallerie V. Mclaughlin's Published Works

Published Works

Vallerie V. Mclaughlin's AcademicInfluence.com Rankings